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Abstract 
Tick-borne diseases (TBD) in dogs have gained in 
significance in German and Austrian veterinary 
practices. The widespread European tick species 
Ixodes ricinus represents an important vector for 
spirochaetes of the Borrelia burgdorferi sensu lato 
group and Rickettsiales such as Anaplasma phago-
cytophilum. The meadow or ornate dog tick (Der-
macentor reticulatus) is an important vector for 
Babesia canis, as is the brown dog tick (Rhipiceph-
alus sanguineus) for Babesia vogeli in the Mediter-
ranean region. The present work covers pathogen 
transmission by tick vectors, including the mech-
anisms and the minimum intervals required, 
in conjunction with possible non-vector-borne 
transmission routes. It also addresses the incuba-
tion periods, pathogenicity and clinical findings 
associated with each pathogen and genospecies 
and presents case examples. Current data on 
prevalence, annual fluctuations and distribution 
in various pre-selected dog populations (sympto-
matic versus asymptomatic) in both countries are 
depicted in maps. Reasons for changes in preva-
lence (especially of Borrelia) are discussed. Criteria 
and algorithms for clinical diagnosis and monitor-
ing in dogs, including case history, direct detection 
(blood smears, molecular detection by species-spe-
cific PCR and sequencing) and indirect methods 
(whole-cell and peptide-based antibody tests), are 
presented, together with laboratory abnormalities 
(haematology, clinical chemistry, urine). The role 
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of anti-C6 antibody concentration (ACAC) and its 
correlation with proteinuria and Lyme nephritis 
are assessed on the basis of new data. Considera-
tion is also given to the importance of blood smears, 
PCR and serology in the case of anaplasmosis and 
babesiosis, and the diagnostic value of combining 
these methods. The relevance of molecular dif-
ferentiation of Anaplasma species (A. phagocyt-
ophilum versus A. platys) and Babesia spp. (large 
versus small forms) in cases of serological cross-
reaction is emphasized. A summary is given of 
methods for prophylaxis using acaricide products 
(collars, spot-on solutions and oral treatments in 
both countries), vaccination (Borrelia and Babesia 
vaccines) and imidocarb-based chemoprophylaxis 
for large Babesia.
Introduction
Tick-borne diseases (TBD) in dogs have gained in 
significance in German and Austrian veterinary 
practices. The widespread European tick species 
Ixodes ricinus is a major vector of spirochaetes 
from the Borrelia burgdorferi sensu lato com-
plex (Bbsl) and Rickettsiales such as Anaplasma 
phagocytophilum. The meadow or ornate dog tick 
(Dermacentor reticulatus) is an important vector 
for Babesia canis, as is the brown dog tick (Rhi-
picephalus sanguineus) for Babesia vogeli in the 
Mediterranean region (Table 1). 
B. burgdorferi, the pathogen responsible for Lyme 
borreliosis (LB), was named after Dr. Willy Burg-
dorfer, who first discovered the bacterium in ticks 
in 1981 (reviewed by Horst 2003; Skotarczak 2014). 
They represent relatively large, helical-shaped (spi-
ral) bacteria belonging to the spirochaetes (order 
Spirochaetales). The Bbsl complex currently com-
prises 19 species, including at least five genospecies 
pathogenic to humans (Borrelia burgdorferi sensu 
stricto / Bbss, Borrelia afzelii, Borrelia bavarien-
sis, Borrelia garinii and Borrelia spielmanii; Her-
zberger et al. 2007; Krupka and Straubinger 2010; 
Margos et al. 2013; Tijsse-Klasen et al. 2013b). 
Based on current information, pathogenicity (in 
the course of experimental and natural infections) 
in the dog has been demonstrated conclusively only 
for Bbss, especially in the light of Koch’s postulates 
complying after experimental infections (Hovius 
et al. 2000; Straubinger 2000; Straubinger et al. 
2000; Liebisch and Liebisch 2003a; Littman et al. 
2006; Wagner et al. 2012; Skotarczak 2014).
A. phagocytophilum is an obligate intracellular 
gram-negative bacterium, belonging to the order 
of Rickettsiales. This bacterium replicates mainly 
in neutrophils and can cause disease in humans, 
horses, dogs, cats and ruminants (Huhn et al. 
2014). Since 2001, the former species Ehrlichia 
equi and Ehrlichia phagocytophila, and the agent 
responsible for human granulocytic ehrlichiosis 
(“HGE agent”), have been reclassified as a new spe-
cies A. phagocytophilum on the basis of molecular 
data (16S rRNA gene; Dumler et al. 2001). These 
bacteria bind to glycoproteins on the surface of neu-
trophils and are incorporated into the cells through 
caveolae-mediated endocytosis. Thereafter, they 
prevent endosome-lysosome fusion and reproduce 
in membrane-bound vesicles, forming microcolo-
nies called morulae (Carrade et al. 2009). A recent 
study showed furthermore that A. phagocytophilum 
was able to invade endothelial cells in vitro and 
that transmission of bacteria from microvascular 
endothelial cells to granulocytes occurred under 
flow conditions (Wang et al. 2015).
Babesia are protozoan agents belonging to the piro-
plasms (family Babesiidae, order Piroplasmida), 
and are the most important blood parasites found 
in domestic mammals. Canine babesiosis occurs 
worldwide. Intraerythrocytic parasites in dogs 
with symptoms comparable with babesiosis (fever, 
anaemia, splenomegaly) were first described in 
South Africa in 1893; in Europe, they were first 
described in Italy in 1895, some years after bovine 
babesiosis was first described by the Romanian 
Victor Babes in 1888 (Babes 1888; Piana and Galli-
Valerio 1895; Baneth 2013). Until a few years ago, 
canine babesiosis was induced by three species of 
a large Babesia (merozoite size 3 – 5 μm), Babesia 
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canis, Babesia vogeli and Babesia rossi (formerly 
Babesia canis subsp. canis, B. canis subsp. vogeli 
and B. canis subsp. rossi), and one small Babesia 
(1 – 3 μm), B. gibsoni (Uilenberg et al. 1989; Zahl-
er et al. 1998; Carret et al. 1999; Irwin 2009; Ogo 
et al. 2011). Recently, however, molecular studies 
resulted in the addition of further species. There 
are now at least nine genetically different species 
recognized (Tables 2 – 3). The recent findings of 
Babesia annae in foxes in Germany, Austria and 
Hungary (see Table 3) are intriguing, as no con-
current infections in dogs were reported from the 
corresponding areas. The provisional assignment 
of this agent as “Theileria annae” is controversial, 
because the organism is phylogenetically closer 
to Babesia microti. Typical features of the genus 
Theileria, such as pre-erythrocytic stages or pau-
city of transovarial transmission in the tick vector, 
have not been proven for B. annae (Dixit et al. 2010; 
Simões et al. 2011). One current study assign this 
organism as Babesia vulpes sp. nov., after its natu-
ral host Vulpes vulpes (Baneth et al. 2015).
Prevalence / occurrence and distribution
The first large-scale, methodically and geographi-
cally comprehensive serological analysis in the 
field of canine TBD in Germany was conducted in 
the form of a countrywide study with 5,881 sam-
ples from dogs tested (Krupka et al. 2007). Serum 
samples from 3,005 dogs (group A; not pre-select-
ed) and 2,876 dogs (group B; showing symptoms 
of borreliosis) were submitted to two different 
Table 1  Tick-borne infections: vectors, pathogens and occurrence (sources include Olmeda-Garcia et al. 1993; Dongus 
et al. 1996; de la Fuente et al. 2008; Brianti et al. 2012; Petney et al. 2012; Deplazes et al. 2013; Ionita et al. 2013; 
Krücken et al. 2013; Tijsse-Klasen et al. 2013a; Najm et al. 2014; Rizzoli et al. 2014); * There is evidence that other 
Ixodes spp. such as I. hexagonus may also act as vectors for Lyme borreliae or Anaplasma phagocytophilum (Pet-
ney et al. 2012); ** Relative humidity; ***Currently assumed to be a cryptic species complex under the name “R. 
sanguineus sensu lato” with several different species included, presumed different distribution, host specificity 
and vector competence (Dantas-Torres & Otranto 2014a).
Vectors Appearance Potential vector for...
Occurrence in Germany 
and Austria?; habitat
Ixodes ricinus:
the Castor bean 
tick*
Borrelia burgdorferi / Borrelia miya-
motoi, Anaplasma phagocytophilum, 
tick-borne encephalitis virus, louping 
ill virus / Eyach virus / Tribec virus, 
Babesia divergens / B. microti /  
B. venatorum (B. capreoli, B. annae?), 
Rickettsia helvetica / R. monacensis,
Candidatus Neoehrlichia mikurensis, 
Bartonella henselae
yes; humid habitats  
(>75% RH**): especially
forest borders, roadsides, 




the Ornate dog tick
Babesia canis / B. caballi,
Theileria equi, Francisella tularensis, 
Rickettsia raoultii / R. slovaca /  
R. helvetica
yes; local foci: humid forest 




the Brown dog tick
Babesia vogeli / B. gibsoni, Anaplasma 
platys, Ehrlichia / Hepatozoon canis, 
Dipetalonema dracunculoides,
Cercopithifilaria spp., Rickettsia  
conorii / R. massiliae, Bartonella  
vinsonii subsp. berkhoffi
only temporary as an
outdoor tick; locally as  
an imported, indoor 
(“domestic”) populations  




laboratories where they were investigated using a 
serological rapid test (SNAP® 4Dx®) for the pres-
ence of specific antibodies to Borrelia C6 antigen 
(not induced by vaccination, see below). In group 
A, 7.7 % of the dogs (232 / 3,005; 95 % confidence 
interval (CI): 6.8 – 8.7) and 11.8 % of the dogs in 
group B (340 / 2,876; 95 % CI: 10.7 – 13.1) tested 
positive (statistically significant difference of 
p < 0.001; chi-square (CS) test). Overall, regional 
seroprevalences of 1.9 % to 10.3 % were found for 
B. burgdorferi (group A). Similar seroprevalence 
was observed for humans in a recent study from 
Germany (9.4 %; 741 / 6,945), with significant corre-
lation for seropositivity in southern Germany, male 
sex and residence in rural areas. Interestingly, 
having a dog / cat in the house was not associated 
with a higher risk for seropositivity (Wilking et al. 
2015). Within the above mentioned canine group 
A 3 % of the dogs (91 / 3,005; 95 % CI: 2.4 – 3.7) also 
showed antibodies to A. phagocytophilum (Fig. 1). 
The seroprevalence for A. phagocytophilum (total 
samples tested 5,683; antibodies to MSP2 (P44) 
antigen) was 21.5 % (95 % CI: 20.5 – 22.6). It can 
therefore be assumed that at least one fifth of dogs 
in Germany had contact with this agent. Overall, 
regional seroprevalences of 17.6 % to 31.1 % were 
found for Anaplasma spp. (Krupka et al. 2007). 
In comparison, the seroprevalence with the same 
test (SNAP® 4Dx®) for Borrelia and Anaplasma 
in Poland (3,094 canine samples) was 3.75 % and 
12.31 %, respectively (Krämer et al. 2014). Even 
lower rates (1.09 % for Borrelia and 2.72 % for Ana-
plasma) were found in in France (the same test; 
919 dogs; Pantchev et al. 2009).
To document the presence of A. phagocytophilum 
and Bbsl in dogs in Austria, routine diagnostic data 
from the authors’ laboratory were evaluated retro-
spectively (previously unpublished data; methods 
according to Dyachenko et al. 2012). In April/May 
2011, Anaplasma spp. real-time PCR was used to 
Table 2  Current Babesia species in the dog (large forms): at least six genetically different species / isolates (according to 
Beck et al. 2009; Irwin 2009; Birkenheuer 2012).
Species Synonym Vector Distribution special features /  
clinical findings




global throughout the 
tropics and subtropics, 
Mediterranean region
in colder zones, vector also 
adapted to indoor, year-round 
tempered climate of buildings




Europe haemolytic anaemia, fever; 
moderate virulence






haemolysis, immune disease; 
high virulence






North Carolina (USA) thrombocytopenia, haemolytic 
anaemia, leukopenia, pigmen-
turia
Babesia sp. unnamed large 




United Kingdom thrombocytopenia, haemolytic 
anaemia, leukopenia, pigmen-
turia
Babesia caballi – unknown 
(D. reticulatus?)
Croatia molecular detection only
*shows weak virulence for adult dogs but can also take a severe course in the presence of predisposing factors (young 
dogs, immunosuppression (Cushing’s disease,  corticosteroid administration or co-infections)); **apparently the Babesia 
species from NC (“Babesia sp. coco”) affect mainly immunosuppressed dogs; in vitro, it shows few ultrastructural dif-
ferences compared to other Babesia spp.; according to the phylogenetic results (18S rRNA) of a current study, this large 








Fig. 1  phagocytophilum and Borrelia burgdorferi in Germany: origin of simultaneously detected anti-
bodies by postcode (map produced using EasyMap; positions correspond to submitters‘ postcodes).
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test a total of 50 EDTA blood samples submitted 
by veterinarians in Austria (this test had been spe-
cifically requested, so the dogs were presumably 
showing clinical signs of infection). Eight out of 
50 samples (16 %; 95 % CI: 7.1 – 29.1) tested posi-
tive. In comparison, a total of 30 samples were 
tested in the same period in 2010; five of these 
tested positive (16.7 %; 95 % CI: 5.5 – 34.7). One hun-
dred and sixty-four dogs were tested serologically 
for antibodies to Borrelia spp. C6 antigen in April/
May 2011 (serum samples; again submitted by 
Austrian veterinary surgeons specifically request-
ing this test), and seven were positive (4.3 %; 95 % 
CI: 1.7 – 8.6). In comparison, a total of 90 samples 
were tested in the same period in 2010; five of these 
tested positive (5.6 %; 95 % CI: 1.8 – 12.5). Strik-
ingly, much larger numbers of samples were sub-
mitted for both tests in 2011 (increases of approx. 
67 % and 83 % respectively compared with 2010). 
However, the differences in positive percentages 
for the two years were not statistically significant 
(p = 0.644 for Borrelia and p = 0.938 for Anaplas-
ma spp.; CS test). Regarding the distribution of 
positive samples, some federal states showed an 
overlapping incidence of both organisms (Vienna, 
Lower/Upper Austria and Carinthia). In other 
regions, only Anaplasma (Vorarlberg, Styria and 
Burgenland) or only Borrelia (Tirol) was detected. 
Salzburg was the only state with no positive cases 
(Fig. 2).
Previously, canine babesiosis was typically associ-
ated with travel to Mediterranean countries. In a 
study conducted in 2005 and 2006, blood samples 
from 5,483 dogs living in Germany with a history of 
travel were tested for relevant pathogens. Babesia 
species (DNA detection by means of conventional 
PCR technique) were detected in 2.4 % of these 
samples (Hirsch and Pantchev 2008). However, 
canine babesiosis is increasingly endemic in both 
Germany (Barutzki et al. 2007) and Switzerland 
Table 3  Current Babesia / Theileria species in the dog (small forms): at least five genetically different species (according 
to Zahler et al. 2000a,b; Beck et al. 2009; Irwin 2009; Birkenheuer 2012; Falkenö et al. 2013; Najm et al. 2014; 
Duscher et al. 2014; Gallusova et al. 2014; Rosa et al. 2014; Baneth et al. 2015; Farkas et al. 2015).
Species Synonym Vector Distribution
special features /  
clinical findings







mainly in Asia,  
sporadically also in 
Africa, Australia, 
Europe, North and 
South America 
outside Asia, infection 
often associated with  
pit bull terriers and other 




“Small Babesia sp.” 
California isolate
unknown (a wild 
animal reservoir is 
assumed)
California haemolytic anaemia,  
vomitus
Babesia annae Babesia microti-like, 
Theileria annae; 
Babesia vulpes sp. 
nov.; Babesia Span-




tugal, Croatia, Sweden, 
USA; Germany / Austria 
/ Hungary (only in fox)
severe haemolytic  
anaemia, eosinophilia, 
renal involvement
Theileria equi Babesia equi unknown Spain, Croatia, France, 
Romania, Jordan; 
South Africa





– unknown Spain molecular detection only
Theileria sp. unnamed Theileria 
sp., South African 
Theileria sp.





(Schaarschmidt et al. 2013). This is believed to be 
the result of dogs introducing infected ticks, which 
have subsequently found suitable biotopes (for 
example, due to re-naturalization of agricultural 
areas) and climatic conditions (Heile et al. 2006). 
In a recent study, a new B. canis ELISA was used 
to test 4,579 canine samples from Germany for 
B. canis antibodies as part of travel disease pro-
files (no immediate suspicion of babesiosis) and 
937 samples from dogs with suspected babesiosis 
(Pantchev 2012a). Because a travel disease profile 
had been ordered, the dogs in the first group were 
assumed to have travelled outside Germany; in the 
second group, a history of travel could not be entire-
ly ruled out. According to the test manufacturer, 
the sensitivity and the specificity of the B. canis 
ELISA compared with the indirect immunofluores-
cence assay (IFA) (671 sera tested using four dif-
ferent IFAs) are 91.6 % and 95.4 %, respectively. In 
relation to a “gold standard” IFA validated at a uni-
versity institute according to strict scientific crite-
ria (287 sera), sensitivity and specificity are as high 
as 96.3 % and 100 %. This ELISA is currently the 
only test authorized by the German Friedrich Löf-
fler Institute for the detection of B. canis-specific 
antibodies in dogs. However, it shows cross-reac-
tivity with other Babesia spp. (such as B. vogeli, 
Dyachenko et al. 2012) as well as B. gibsoni and 
Rangelia vitalii (own unpublished observations; 
see below). This whole-cell based assay can there-
fore be regarded as more piroplasma-specific. 
Three hundred and nineteen dogs (travel disease 
profile) within the above-mentioned study tested 
positive for antibodies (7 %; 95 % CI: 6.2 – 7.7) and 
a further 112 samples were borderline (2.4 %). In 
dogs with suspected babesiosis, higher propor-
tions of samples were seropositive (12.7 %; 95 % CI: 
10.6 – 15; significant difference of p < 0.001, CS test) 
and 3.5 % of samples were borderline. Regard-
ing the distribution of positive samples in both 
groups within the German federal states, it can be 
observed, that only dogs with a history of travel 
tested positive in four federal states, and one state 
had no cases at all (Fig. 3). Whether this result is 
due to the absence of endemic canine babesiosis in 
these states, or to the simple fact that insufficient 
samples were submitted, should be a subject for 
further studies.
The occurrence and distribution of B. canis infec-
tion in dogs in Austria was established using the 
Fig. 2 A. phagocytophilum (blue; real-time PCR)  
occurrence and B. burgdorferi (red; anti-C6 antibodies) 
seroprevalence in Austria: origin of positive samples by 
postcode (map produced using RegioGraph; positions  
correspond to submitters’ postcodes).
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Fig. 3 Babesia canis in Germany: Origin of seropositive dogs with a history of travel (blue; n = 319) and suspected 




same Babesia ELISA (see above; previously unpub-
lished data). The serum samples were submitted 
to the authors’ laboratory by veterinarians in Aus-
tria from 2012 to 2013. Two hundred and fifty-nine 
samples in group 1 were tested either in response 
to a direct request for a Babesia spp. antibody test 
(n = 70; 27 %) or as a part of a serological tick profile 
(n = 189; 73 %). As a comparison, a second group 
was assessed over the same time period (group 2; 
n = 172). Animals in group 2 were assumed to have 
a travel history, because the serum samples were 
submitted by the veterinarian as part of a travel 
disease profile. In group 1 (mostly comprising “tick 
profiles”) 28 samples tested positive (10.8 %; 95 % 
CI: 7.3 – 15.2; red in Fig. 4) and 6 samples were bor-
derline (2.3 %). As part of the travel disease profile, 
however, only 8 dogs tested positive (4.7 %; 95 % CI: 
2 – 9; blue in Fig. 4), which is significantly fewer 
than in group 1 (p = 0.024; CS test). Additionally, 
six samples in group 2 tested borderline (3.5 %). As 
can be deduced from Figure 4, there appears to be 
a cluster of seropositive dogs in the eastern part 
of Austria.
Pathogen transmission and incubation period
Various mechanisms are required to activate the 
relevant pathogen in the tick. In general, trans-
mission of bacteria and parasites does not occur 
immediately. The shortest transmission inter-
vals reported are 16 to 65 hours for Borrelia and 
24 hours for Anaplasma (Crippa et al. 2002; Kahl 
et al. 1998; Diniz and Breitschwerdt 2012). Bor-
relia spp. produce various outer surface proteins 
(“Osp”), which enable the spirochaetes to adapt to 
a wide range of environmental conditions (Kenedy 
et al., 2012). Borrelia organisms in the tick’s gut 
express mainly OspA, which allows the bacteria to 
adhere to the tick receptor for OspA (“TROSPA”; 
Tsao 2009). Contact with the host’s skin causes 
a temperature rise in the tick, which triggers an 
activity signal in Borrelia organisms, enabling 
them to migrate from the tick’s gut to its salivary 
glands. Following contact with blood, OspA (and 
OspB) are replaced within 36 to 48 hours by newly 
produced OspC, which binds to the tick salivary 
protein Salp15 (Kenedy et al. 2012). After 24 to 
48 hours, Borrelia organisms are transmitted to 
the dog (Radolf and Caimano 2008; Straubinger 
and Pantchev 2010). In the mammalian host, 
Fig. 4 Babesia canis seroprevalence in Austria:  
origin of seropositive dogs in group 1 (predominantly 
tested as part of a tick profile; red, n = 28) and group 2 
(“travel disease profile”; blue, n = 8; map produced  




spirochaetes express the protein VlsE (variable 
major protein-like sequence, expressed) on their 
surface. The variability of this protein allows Bor-
relia to evade the host’s immune defences (Kenedy 
et al. 2012). A shift in the outer surface proteins 
seems to be crucial for infection (Appel et al. 1993; 
Radolf and Caimano 2008). In experimental stud-
ies it was shown that the incubation period in the 
dog is between two and five months (Appel et al. 
1993; Straubinger 2000; Straubinger et al. 2000; 
Wagner et al. 2012). Therefore, no clinical signs 
were observed in dogs that had not previously 
seroconverted (Appel et al. 1993). In contrast, the 
incubation period for anaplasmosis following a 
tick bite or experimental (i.v.) infection is reported 
to be 1 to 2 weeks (Scorpio et al. 2011; Diniz and 
Breitschwerdt 2012), which can precede serocon-
version (see below). Shorter transmission intervals 
may exceptionally occur. For example, occasional 
cases of systemic infection with Borrelia spp. in 
the tick were described, with Borrelia present in 
the salivary glands before tick attachement (also 
described for A. phagocytophilum; Crippa et al. 
2002; Diniz and Breitschwerdt 2012). Earlier trans-
mission is also possible, if previously attached (and 
thus “activated”) ticks infest a new host. Moreover, 
Fig. 5 Life cycle of Ixodes ricinus and transmission of rodent-associated Borrelia spp. (e.g. B. afzelii / Bbss; sources  
include Tsao 2009; Greene et al. 2012; Tappe et al. 2014); within the figure of Ixodes nymph (centre), the female is 
shown only for size comparison; * see text
dogs, cats, humans,  
hedgehogs, horses, 














I. ricinus appears to transmit B. afzelii more rap-
idly than Bbss (Crippa et al. 2002; Moehrle and 
Rassner 2002). It is generally assumed that trans-
mission of Bbsl takes place via nymphs and adult 
ticks, and specifically that larvae become infected 
by feeding on infected reservoir hosts (e.g. rodents), 
followed by transstadial transmission of Borrelia 
(illustrated in Fig. 5; applies similarly to A. phago-
cytophilum). Whether a transovarial transmission 
of Bbsl can take place in the tick, as proposed fol-
lowing increased molecular detection in larvae in 
a recent study (Tappe et al. 2014), or the transo-
varially transmitted agent is actually Borrelia miy-
amotoi (Rollend et al. 2013), has to be evaluated 
in further studies. Even if larvae did contain Bbsl 
in sufficient amounts for transmission, the risk to 
dogs is put into perspective by the fact that these 
larvae live primarily at ground level, and their 
preferred hosts are small mammals and birds 
(Liebisch and Liebisch 2003b; Greene et al. 2012; 
Deplazes et al. 2013). This is supported by a recent 
study from Switzerland, in which only 0.5 % of col-
lected ticks from dogs we identified as being larvae 
(Eichenberger et al. 2015). Non-vector-borne trans-
mission of A. phagocytophilum in humans through 
blood transfusions (Annen et al. 2012) or perinatal 
infection (Horowitz et al. 1998; Dhand et al. 2007) 
has been described. Moreover, transplacental 
transmission as a result of experimental infection 
is possible in ruminants (Diniz and Breitschwerdt 
2012) and was also confirmed after natural con-
genital infection in a calf in northern Germany 
(Henniger et al. 2013). Vertical transmission of 
Bbss did not occur under experimental conditions 
in dogs (maternal antibodies declined to negative 
4 weeks postpartum; Appel et al. 1993). Vertical 
transmission of Borrelia spp. and other non-vector-
borne modes of transmission (via semen, urine, or 
blood) are unlikely in the dog under natural con-
ditions (Appel et al. 1993; Greene et al. 2012). 
According to guidelines on the collection, storage, 
transport and administration of blood and blood 
products in veterinary medicine, issued by the 
German Federal Office of Consumer Protection and 
Food Safety, dogs used as blood donors in Germany 
should be tested by PCR for Anaplasma spp. 
(A. phagocytophilum) and Babesia spp. (B. canis; see 




A striking feature of Babesia species is not only 
the transstadial but also the efficient transovar-
ial transmission in the tick. By means of vertical 
transmission to the next 3 to 4 generations, tick 
populations in an endemic region can remain in - 
fected for several years, despite having no oppor-
tunity for reinfection (Deplazes et al. 2013). This 
ensures long-term survival in the tick population 
(distribution strategy; Chauvin et al. 2009). This 
process is limited to some extent because only 10 to 
20 % of the tick eggs are infected, and infected 
females produce fewer eggs (Deplazes et al. 2013). 
The development of Babesia in the tick, specifically 
the infestation of the salivary glands accompanied 
by the production of sporozoites, does not happen 
immediately, but is triggered by nervous stimula-
tion of various organs. When ticks attach to the 
host, developmental stages of Babesia known as 
kinetes are released. These enter the tick’s salivary 
glands via the haemolymph. Dogs exposed experi-
mentally to D. reticulatus containing B. canis test-
ed positive for Babesia (PCR, blood smears) after 
a 72-hour infestation; males which had already 
had a blood meal were an exception in terms of 
immediate transmission (Heile and Schein 2007). 
The same study showed that nymphs already have 
the ability to transmit B. canis. However, because 
nymphs rarely infest dogs, this mode of transmis-
sion plays only a minor role from an epidemiologi-
cal perspective. The incubation period of Babesia 
in the dog is reported to be 7 to 21 days p.i. (Bel-
ton 2003; Deplazes et al. 2006). Non-vector-borne 
transmission routes may include blood transfusion, 
as shown in the case of B. canis in an experimental 
design (Brandao et al. 2003) or in the case of B. gib-
soni (Belton 2003; Boozer and Macintire 2005). In 
regard to B. gibsoni, there is also speculation about 
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direct dog-to-dog transmission via bite wounds, 
saliva or ingested blood (fighting dogs), and trans-
placental transmission (B. canis, B. gibsoni and 
B. annae) also appears to be possible (Belton 2003; 
Boozer and Macintire 2005; Irwin 2009; Ayoob 
et al. 2010; Ogo et al. 2011; Simões et al. 2011; 
Mierzejewska et al. 2014).
Diagnostics
Lyme borreliosis (LB)
The presumptive diagnosis of LB in dogs implies 
several criteria (according to Littman et al. 2006; 
Krupka and Straubinger 2010). These include a 
history with regard to tick exposure and living in 
endemic regions, diagnostic evidence of infection 
with the pathogen, exclusion of differential diag-
noses, compatible clinical symptoms, and response 
to specific treatment including monitoring of treat-
ment success. Detection by direct methods (PCR 
and/or culture) ante mortem is difficult and of little 
practical relevance. Borrelia organisms are rarely 
detected in body fluids such as blood (Fig. 6), urine 
(bladder involvement is also rare), synovial fluid 
or cerebrospinal fluid (Leschnik et al. 2010; Krim-
er et al. 2011; Susta et al. 2012). They are more 
commonly found in connective tissue, fascias, joint 
capsule (most promising in the affected joint), skin 
(near the tick bite), lymph nodes, muscle (including 
the heart), etc. (frequently in low numbers at the 
time of detection; Appel et al. 1993; Chang et al. 
1996; Straubinger 2000; Chou et al. 2006). The 
majority of dogs first develop lameness in the joint 
closest to the site of tick attachment, which further 
supports the fact that B. burgdoferi does not dis-
seminate throughout the body via the blood stream 
(Straubinger et al. 1998). Direct methods in many 
cases produce false-negative results, because tis-
sue samples commonly contain few or no bacteria 
at the time of collection, so serology is widely used. 
However, the only reliable way to differentiate the 
genospecies is direct detection followed by molecu-
lar characterization (as is frequently performed 
in tick studies; Skotarczak 2014), because the rel-
evant antigens display serological cross-reactivity 
(Hovius et al. 2000). As a result, it is not currently 
possible to use different serological tests (enzyme 
immunoassays or immunoblots) based on individu-
al genospecies or their antigens to perform reliable 
serological differentiation (Kurzova et al. 2014).
Four aspects should be considered when interpret-
ing positive serological results. Serological tests 
detect circulating antibodies to an infectious agent, 
which may indicate active infection with that 
agent, previous infection or exposure, vaccination, 
or cross-reactivity with another (generally closely 
related) organism. These points should be consid-
ered, when evaluating serological tests for Borrelia 
spp.-specific antibodies. In human and veterinary 
medicine, antibody detection using specific pep-
tides such as C6 is becoming increasingly popular 
(e.g. Liang et al. 1999a; Embers et al. 2007; Krup-
ka and Straubinger 2010; Wagner et al. 2012), as 
they show advantages over other methods, taking 
into account the four points mentioned above. The 
C6 peptide is part of VlsE, a 35-kDa surface lipo-
protein of Borrelia burgdorferi (Kenedy et al. 2012). 
IR6 (synthetic peptide = C6) is the most immuno-
dominant of six invariable regions (IR1 – IR6) within 
the central variable domain (six variable regions, 
VRI – VRVI, interlaced with the invariable regions; 
Fig. 6 Borrelia hispanica in the stained blood smear of a 
dog: in contrast to relapsing-fever (RF), Lyme borreliosis 
(LB) spirochetes are not detected in blood samples.
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Liang et al. 1999b; Embers et al. 2007; Fig. 7). In 
addition, C6 is conserved among different Borrelia 
species (Liang et al. 2000a). The VlsE gene locus is 
located on a plasmid (lp28 – 1; Brisson et al. 2012; 
Embers et al. 2012), its expression is suppressed 
in the tick (Bykowski et al. 2006; Tilly et al. 2013) 
and drastically upregulated in the host. Moreover, 
recombination takes place only in the host, not in 
the tick or in in vitro cultures (Lin et al. 2009). 
Antibodies to Borrelia C6 antigen are not induced 
by vaccination in the dog (O’Connor et al. 2004; 
Goldstein et al. 2007), possibly due to lost of VlsE 
expression after repeated serial passage of cul-
tured spirochaetes (Liang et al. 1999a,b; O’Connor 
et al. 2004; Lin et al. 2009). According to current 
scientific knowledge, VlsE is also one of the most 
important virulence factors of Lyme borreliae, pre-
venting their elimination by the immune system 
and triggering a persistent infection in the host. 
This is made possible by constant alternation in the 
six variable regions (Lin et al. 2009; Brisson et al. 
2012; Kenedy et al. 2012).
The advantage of Borrelia C6-based tests over 
previous methods (IgM/IgG-ELISA or IFA) is the 
absence of a cross-reaction with vaccine-induced 
antibodies (O’Connor et al. 2004; Töpfer 2005; Gold-
stein et al. 2007) or with antibodies to other spi-
rochaetes such as Leptospira (Liang et al. 2000b). 
Thus, C6 represents a diagnostic approach that 
facilitates DIVA (Differentiation of Infected from 
Vaccinated Animals). Whole-cell-based assays can 
cross-react with other spirochaetes as shown e.g. 
for Leptospira species (Štefančikova et al. 2008) or 
with vaccination (e.g. Gauthier and Mansfield 1999; 
Straubinger et al. 2002; Töpfer 2005). Anti-C6 anti-
bodies also represent an early marker of infection 
from 21 to 35 days p.i. (Wagner et al. 2012) and 
persist for at least 12 months in untreated dogs 
(Levy et al. 2008). After treatment, anti-C6 anti-
body concentrations (ACAC) may drop within 3 to 
6 months (a decrease of more than 58.3 % was seen 
after 6 months in animals with an initial concen-
tration over 29 U/ml; Levy et al. 2008), whereas 
the values in whole-cell-based tests and OspF-
based tests do not fall to the same extent (Straub-
inger 2000; Straubinger et al. 2000; Littman 2013; 
Fig. 8). Additionally, Goldstein et al. (2007) showed 
a 93 % correlation between a commercially available 
C6 test and an immunoblot test with regard to the 
diagnosis of natural infection in the dog. Thus the 
last two criteria (antibody persistence and decrease 
in concentration after treatment) also emphasize 
that C6 can be viewed as a marker of active infec-
tion and can be used to monitor treatment success. 
This has also been shown in experimental infection 
in monkeys (Embers et al. 2012).
 
 
Fig. 7 Structure of VlsE and origin of C6 (modified according to Liang et al. 2000b).
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S31
EctoPARASitES EctoPARASitES
For correct diagnosis it is also important to rule out 
potential differential diagnoses, bearing in mind 
the travel history of the dog and potential infec-
tions from abroad such as Leishmania infantum 
or Ehrlichia canis. Useful tests in this regard are 
listed by Littman et al. (2006), Greene et al. (2012) 
and Pantchev (2012b). They include the following 
examinations: routine laboratory tests (haematol-
ogy, clinical chemistry, urine analysis), tests for 
other infectious agents (serology, PCR and anti-
gen detection if necessary) and immune-mediated 
diseases (rheumatoid factor, antinuclear antibod-
ies or Coombs test), x-rays of one or more limbs, 
joint tap for cytology and culture (up to 76,000 cells/
microlitre (normal <3000), up to 97% of cells neu-
trophils (Straubinger et al. 1998), increased protein 
concentration and turbidity are compatible with 
Lyme arthritis), tumour detection (thoracic x-ray, 
abdominal ultrasound, fine needle aspiration of 
lymph nodes and bone marrow cytology). The pro-
cedure for a Borrelia-positive dog is shown in Fig. 9. 
Additionally, Susta et al. (2012) found an inflamed 
or borderline synovial aspirate (100-cell differential 
count; inflamed if > 20 % neutrophils, borderline at 
8 – 19 % and non-inflamed when < 8 % neutrophils) 
in 47 % (8 / 17) of experimentally infected dogs. 
Moreover, post-mortem histopathological scoring 
of the synovial membrane (elbows and stifles), using 
a proposed grading scheme, was a reliable method 
for discriminating infected and non-infected ani-
mals (88.2 % sensitivity and 100 % specificity).
Fig. 8 Quant C6 ELISA for determination of anti-C6 antibody concentration applied to monitor treatment success 
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 As Fig. 9 shows, it is important to test Borrelia-
positive dogs for proteinuria. An association is 
assumed between Borrelia infection and renal 
disease, termed “Lyme-associated protein-losing 
nephropathy” (PLN) or “Lyme nephritis” (LN). In 
single studies, breeds commonly affected included 
labrador retriever, golden retriever and sheltie. 
In one study, 17 out of 20 Bernese mountain dogs 
were seropositive (IgG-IFA), but, because the 
immunohistochemical studies were negative, a 
familial nephropathy was assumed (Minkus et al. 
1994). Dogs with suspected LN were younger (53 % 
< 5 years with an average of 5.6 years) than dogs 
with similar diseases of different genesis (7.1 years 
for glomerulonephritis and 7.8 years for amyloi-
dosis). There was no gender predisposition, and 
the animals were usually presented in summer 
and autumn with acute or chronic kidney disease 
accompanied by anorexia, vomitus, thromboembo-
lism, hypertension, oedema, oliguria or pigmentu-
ria (Dambach et al. 1997; Littman et al. 2006; Chou 
et al. 2006; Goldstein et al. 2013; Littman 2013). 
Clinical signs associated with the central nervous 
system (CNS) can also occur in association with 
nephropathy, for example as a consequence of vas-
culitis, hypertension, thromboembolism and urae-
mic encephalopathy. Laboratory abnormalities 
include non-regenerative anaemia, thrombocyto-
penia, hypoalbuminaemia, azotaemia, hyperphos-
phataemia and proteinuria, with a urine specific 
gravity below 1.022. In contrast to leptospirosis, LN 
is not the consequence of direct renal invasion of 
spirochaetes, but it is regarded as an immune-medi-
ated disease. It is described as an infection-related 
sterile immune-complex glomerulonephritis with 
deposition of Borrelia-specific antigen-antibody 
complexes. This renal form is frequently IHC-
positive for antigen but PCR-negative for DNA, 
with a p.i. disease incidence of 1.85 % (Dambach 
et al. 1997; Chou et al. 2006; Hovius 2013; Littman 
2013). In regard to histopathology, LN is present-
ed as an immune-mediated membranoprolifera-
tive glomerulonephritis (“MPGN”), combined with 
lympho-plasmocytic interstitial infiltrates and 
tubulonephrosis. In one study, 27 out of 32 dogs 
(84 %) with glomerulonephritis diagnosed by his-
tology showed positive IHC staining of renal tis-
sues (rabbit-derived polyclonal antiserum directed 
against a whole-cell preparation of B. burgdorferi 
strain B31 was used; Chou et al. 2006). Currently, 
it is not well understood whether LN is under-
recognized, whether mild or early forms exist, and 
whether it responds to early intervention. Accord-
ing to Littman (2013), it may be under-diagnosed, 
especially in the case of mild or early forms in Bor-
relia-positive but asymptomatic dogs, or in positive 
symptomatic dogs not tested for proteinuria. On 
the other hand, LN may be over-diagnosed where 
a proteinuria in Borrelia-positive dogs is merely 
coincidental, due to urinary tract disease such as 
pyelonephritis, leptospirosis or a PLN of different 
genesis (infectious, genetic, systemic lupus ery-
thematosus, neoplasia or haemolytic uraemic syn-
drome). There is also a need for further clarification 
as to whether non-Borrelia spp.-specific immune 
complex deposition also occurs in cases of LN. One 
study found that 16 % of suspected LN cases did 
not show a positive IHC response to immune com-
plexes (Chou et al. 2006). A further open question 
remains as to whether the specific immune com-
plexes cause LN or are only passively deposited 
there (or not adequately eliminated) due to host-
pathogen factors such as the Borrelia spp. strain, 
genetic podocytopathies or immunopathological 
changes (Littman 2013). The latter hypothesis is 
supported by a recent case in which the authors 
considered LN as the expression of a breed-related 
(soft-coated wheaten terrier / SCWT) PLN, in which 
the Borrelia spp. antigens may have triggered the 
development of the initial immune complexes 
(Horney and Stojanovic 2013). This is addition-
ally corroborated by a recent human case of Lyme-
associated glomerulonephritis with a probable 
underlying IgA nephropathy at baseline (chronic 
ethanolic hepatitis with polyclonal increase of IgA; 
Rolla et al. 2013).
There are currently no officially recognized tests 
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Fig. 9  Flowchart for the 
Borrelia-seropositive dog 
(modifi ed according to 
Littman et al. 2006; Pantchev 
2012b; * International Renal 
Interest Society (see also 
Goldstein et al. 2013)
LN, although some attempts to fill this gap were 
made in the past. Despite monthly tick prophy-
laxis, a study group of dogs showed 18.7 % sero-
positivity using a C6-antibody-based test (SNAP® 
3Dx®), but no correlation with microalbuminuria 
(present in 6.1 %; E.R.D. HealthScreen Urine Test) 
was found (Goldstein et al. 2007). This group con-
sisted of young, clinically normal labradors and 
golden retrievers (median age 1.5 years; n = 268), in 
a Lyme-endemic region in the USA. However, this 
study only compared qualitative C6 seropositivity 
with microalbuminuria, and then only in young 
dogs. In experimentally infected dogs, Susta et al. 
(2012) found an urine protein: creatinine ratio 
(UPC) 120 days p.i. that was elevated, compared 
with the ratio 90 days p.i. in 8 out of 17 animals. 
However, the difference was not statistically signi-
ficant, the chosen cut-off of <1 appears to be too 
high (see below) and the method used to deter-
mine the UPC was not stated. In a naturally 
infected, 6-year-old SCWT in Canada, mentioned 
above, which was initially presented with lame-
ness, peripheral lymphadenopathy, anorexia and 
weakness, ACAC of 176 U/ml and an elevated UPC 
(8.58) were found (Horney and Stojanovic 2013). 
In addition to supportive treatment for a suspect-
ed familial, breed-related PLN, doxycycline was 
administered (5 mg/kg b.i.d. for 4 weeks). ACAC 
subsequently decreased to 41 U/ml and the UPC to 
1.73. Results of the latter study indicate that ACAC 
could represent a test able to predict which dogs 
are predisposed for development of LN or which 
could facilitate the diagnosis of LN. The correla-
tion between (high) ACAC and proteinuria in dogs 




Recently, we evaluated 103 canine samples: sin-
gle samples of serum and urine provided by Euro-
pean veterinarians with the request for Quant 
C6 ELISA (serum; performed according Levy et al. 
2008) und UPC (urine; for methods see Table 4) 
during 2009 – 2013 (Pantchev 2014). Submissions 
were received from Germany and other Euro-
pean countries (n = 71 from Germany, n = 7 from 
Austria, n = 1 from the Czech Republic, n = 4 from 
Denmark, n = 1 from France, n = 4 from Finland, 
n = 2 from Luxembourg, n = 6 from the Nether-
lands, n = 2 from Norway and n = 5 from Sweden). 
Data were obtained by testing serum and urine 
in parallel. Subsequently, samples were divided 
into 3 groups on the basis of their ACAC: <10, 
10 – 30 and >30 U/ml and a statistical comparison 
(CS) with their UPC value (>= 0.6 as a cut-off) was 
conducted. In total, 55 samples had an UPC greater 
than or equal to 0.6 (53.4 %; 95 % CI: 43.3 – 63.3) 
and 46 dogs showed an ACAC above 30 U/ml 
(44.7 %; 95 % CI: 34.9 – 54.8). Dogs with ACAC in 
the moderate-to-high range (over 30 U/ml; group 
3) also showed a statistically significantly higher 
probability of increased UPC (greater than or equal 
to 0.6 according to IRIS criteria) in urine samples 
compared to dogs with ACAC in the low (10 – 30 U/
ml; group 2) and negative to very low range (under 
10 U/ml; group 1; Table 4).
Table 4  Correlation of anti-C6 antibody concentration (Lyme Quant C6 ELISA in Units/ml) and proteinuria (urine 
protein:creatinine ratio/UPC) based on 103 canine serum and urine samples tested in parallel from the years 
2009 – 2013.
Group Quant C6 Units/ml* anti-C6 antibody level UPC >= 0.6** % and 95% CI***
1 < 10
negative to very low 
positive 
15/39 38.5; 23.3 – 55.4
2 10 – 30 low 5/18 27.8; 9.7 – 53.6
3 > 30 moderate to high 35/46 76.1; 61.2 – 87.5
* allocation according to Levy et al. 2008
** cutoff according to Goldstein et al. 2013 and www.iris-kidney.com; methods in brief:
creatinine determination in mg/dl by means of the Jaffe method (blank corrected, kinetic and photometric),  
determination of protein in mg/dl, turbidimetric (505 nm) after the addition of benzethonium chloride
*** statistical significance of increased UPC with regard to anti-C6 antibody concentration (chi-square test; p < 0.05)
Group 1 versus 2: p = 0.432; not significant
Group 1 versus 3: p < 0.001 significant
Group 2 versus 3: p < 0.001 significant
Groups 1 and 2 (20/57; 35.1%, 95% CI: 22.9 – 48.9) versus 3 (35/46): p < 0.001 significant
Table 5  Total submissions for the Lyme Quant C6 ELISA from the years 2009 – 2013 (n = 15,757 canine serum samples) and 
fractions with an anti-C6 antibody concentration over 30 U/ml.
Year Total samples Samples over 30 U/ml percentage 95 % CI significance*
2009 2944 564 19.2 17.8 – 20.6 ↓; p < 0.001
2010 2882 605 21.0 19.5 – 22.5 ↓; p < 0.001
2011 3288 753 22.9 21.5 – 24.4 ns; p = 0.111
2012 3292 911 27.7 26.2 – 29.2 ↑; p < 0.001
2013 3351 981 29.3 27.7–30.8 ↑; p < 0.001
2009 – 2013 15757 3814 24.2 23.5–24.9 –
* compared to overall result 2009 – 2013 (chi-square test; p < 0.05); ns = not significant; –: not applicable
S35
EctoparasitEs 
On the other hand, groups 1 and 2 showed no dif-
ference with regard to increased UPC (Table 4). 
Dogs from group 3 with ACAC over 30 U/ml (medi-
an 137 U/ml) and elevated UPC (median 6.5) were 
also significantly younger (average age of 5.5 years, 
median 5 years) compared to dogs from groups 
1 and 2 with an elevated UPC (median 1.4), but 
ACAC was less than or equal to 30 U/ml (average 
age of 7.9, median 9 years). This corroborates the 
above mentioned results by Dambach et al. (1997) 
for LN based on 49 canine cases with renal lesions 
putatively associated with B. burgdorferi infection. 
This might indicate that proteinuria in dogs with 
C6 antibody levels lower than or equal to 30 U/ml 
occurs coincidentally and might have another gen-
esis as proposed by Dambach et al. (1997). Within 
Group 3 (>30 U/ml) 11 of 46 dogs (23.9 %; 95% CI: 
12.5 – 38.8) with UPC below 0.6 also showed a lower 
median ACAC (94 versus 137 U/ml); only 4 of these 
11 dogs (36.4 %; 95% CI: 9.8 – 69.9) showed ACAC 
>100 U/ml, compared with 21 of 35 dogs (60 %; 95% 
CI: 42.1 – 76.2) with ACAC >100 U/ml and increased 
UPC; however, this difference was not significant 
(p = 0.435). Another study in dogs showed a median 
UPC of 5.7 (0.47 to 43.4) for glomerulonephritis, 
22.5 (11.2 to 46.6) for amyloidosis and 2.9 (1.5 to 
10.5) for chronic interstitial nephritis (CIN; Center 
et al. 1985). So it is suggested that UPC in dogs 
is usually less than 5 with CIN, whereas primary 
glomerular disease is associated with UPC above 5. 
This corresponds well to the median value of 6.5 
for UPC found in our study for dogs in group 3 (see 
above).
Our data suggest that ACAC, in particular a con-
centration over 30 U/ml, in combination with a cor-
responding history can serve as a marker of LN in 
dogs. Further studies with a larger number of sam-
ples are needed to show whether an ACAC above 
100 U/ml can be regarded as high and may indicate 
an early form of LN in dogs without proteinuria. 
The correlation between high antibody levels and 
disease has generally been disputed (e.g. Littman 
2013). A study in which cases of high ACAC in 
asymptomatic dogs were found (Levy et al. 2008), 
might further support this hypothesis. However, 
no haematology, clinical chemistry or urine analy-
ses were performed by Levy et al. (2008). While 
dogs were clearly described as asymptomatic, they 
were not defined as healthy as suggested by Dan-
tas-Torres and Otranto (2014b). For example, it is 
not known whether these dogs with initial ACAC 
in the moderate-to-high groups (Levy et al. 2008) 
may have had proteinuria. Whether ACAC also cor-
relates with the level of specific immune complexes 
(which were higher in dogs with clinical signs of 
infection), as proposed by Goldstein and Atwater 
(2006), should be a topic for further studies.
In addition to the above retrospective study com-
paring ACAC with UPC in a dog collective (Table 4), 
we evaluated data from 15,757 canine serum sam-
ples submitted by veterinarians for a Lyme Quant 
C6 ELISA only (for methods see above) in 2009 to 
2013 (previously unpublished data). The largest 
fraction of animals was the group under 10 U/ml 
(n = 9,669; 61.4 %; 95 % CI: 60.6 – 62.1). The next 
group with 10 – 30 U/ml contained 14.4 % of the 
cases (n = 2,274; 95 % CI: 13.9 – 15) and the third 
group with ACAC >30 U/ml contained 24.2 % 
(n = 3,814; 95 % CI: 23.5 – 24.9). The differences in 
group 1 and 3 with ACAC under 10 U/ml and over 
30 U/ml were statistically significant compared 
with the dogs with suspected LN (parallel testing 
for ACAC in serum and UPC in urine; Table 4) 
(p = 0.003 and p < 0.001, respectively). Interestingly, 
the percentage of dogs with a request for Lyme 
Quant C6 ELISA and with ACAC over 30 U/ml has 
increased continuously and significantly over the 
years, from 19.2 % (95 % CI: 17.8 – 20.6) in 2009 to 
29.3 % (95 % CI: 27.7 – 30.8) in 2013 (Table 5). It is 
not clear yet what effects might be responsible for 
this significant increase in the proportion of sam-
ples over 30 U/ml. Possible reasons include bet-
ter preselection by the attending veterinarian of 
dogs matching the clinical picture in terms of age, 
breed, etc. Other reasons might be geographical 
(region-specific) influences or vector-related influ-
ences (other Borrelia spp. strains with different 
plasmid content and virulence in the field). New 
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studies differentiating Borrelia spp. by means of 
multilocus sequence typing (MLST) indicate that 
different Bbss strains have different dissemination 
potentials within the organism, pointing to differ-
ent pathogenic properties (Hanincova et al., 2013). 
Other relevant effects might include co-infections 
or co-diseases and a shift in prophylactic methods 
used against ticks and in the frequency or type of 
vaccinations (see below).
In dogs with suspected LN, the importance of 
testing the band pattern in immunoblot assays is 
also highlighted (Littman 2013). In one suspected 
case tested in our laboratory (hunting crossbreed 
dog, 5 years old; previously unpublished data), 
the immunoblot test showed a field infection 
with almost all specific bands reacting positively, 
including VlsE, but without the classic vaccine 
band OspA (Fig. 10). The dog also showed severe 
proteinuria (UPC of 17.8), hypoalbuminaemia, 
azotaemia, anaemia, and a high ACAC of 430 U/ml. 
In comparison, the total IgG level, measured using 
a non-C6/VlsE-based whole-cell ELISA (B. burg-
dorferi veterinary ELISA, Virotech), was relatively 
low at 35.6 units (positive cut-off: 12 units). X-ray 
of the kidneys revealed no abnormalities; a biopsy 
was not performed. No other causes were found 
for the renal damage, following negative tests for 
Leptospira-specific antibodies (microagglutination 
test; MAT), L. infantum-specific antibodies (ELISA; 
Wolf et al. 2014), A. phagocytophilum-specific and 
E. canis-specific antibodies (IFA and SNAP® 4Dx®; 
Dyachenko et al. 2012) and antinuclear antibody 
(IFA, KallestadTM HEp-2 cells, Biorad). A familial 
predisposition was ruled out. The dog was present-
ed at the veterinary practice in August, showing 
fever, fatigue, vomitus and polydipsia.
Fig. 10  Immunoblot of a dog with suspected Lyme nephritis (LN); 1: positive control serum with (below) a protein 
marker with molecular weight of the bands in kDa; 2: suspected LN case: typical band pattern of an infected,  
unvaccinated dog (e.g. VlsE, p83/100, p58, p39, p29/OspD and OspC protein bands present, but OspA (31 kDa;  
predomimant signal associated with vaccination) absent (oval); 3: negative samples (some only reactive for the 
41-kDa flagellin band); 4: prominent OspA band of a vaccinated, non-infected dog (arrow) (Borrelia “MiQ” + VlsE 
ViraBlot/Viramed; secondary antibodies: AP-conjugated goat anti-dog IgG (H+L) – KPL).
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Canine granulocytic anaplasmosis (CAG)
It is essential to take into consideration co-infec-
tions with Borrelia in the diagnostic workflow 
of CAG. Studies show that dogs co-infected with 
A. phagocytophilum and Borrelia spp. run twice the 
risk of developing disease with clinical signs such 
as lameness, fever, lethargy, joint pain (swelling) 
and anorexia compared to with single infections 
with either pathogen (Beall et al. 2008). The con-
current presence of an intracellular (Anaplasma 
spp.) and extracellular (Borrelia spp.) infection 
may lead to an adverse immunological interaction 
during the infection course (Krupka et al. 2007). 
In the majority of dogs, the clinical signs of CAG 
are non-specific and confined to the acute phase of 
the infection (Diniz and Breitschwerdt 2012). Thus, 
“CAG” pose a diagnostic challenge. The criteria for 
diagnosing this disease according to the Centers for 
Disease Control and Prevention (modified accord-
ing to Kohn et al. 2008) include tick contact or blood 
transfusion with clinical symptoms or laboratory 
abnormalities, positive PCR and/or morulae in 
neutrophils and a four-fold increase in antibody 
levels within four weeks. There appears to be no 
breed-related predisposition, although there may 
be a predisposition based on age. For example, in 
the USA 35.3 % of affected dogs were between 8 and 
10 years old, 58.8 % were at least 6 years old and 
Dog from Germany Dog from the Netherlands Dog from Austria 
Age 6 years 10 years 11 years 
Clinical findings  41.3–41.8 °C, peracute 
disease accompanied by 
reluctance to move, 
lethargy, anorexia, pale 
mucous membranes 
40.9 °C, lethargy, upper 
abdominal pain 




CRP (0–9.7 mg/l) 48.8 57.0 63.8 
Thrombocytes 
(150–500 G/l) 
50 unevaluable 118 
Lymphocytes  
(1000–4000 /ul) 
656 748 284 
Monocytes  
(0–500 / ul) 
1031 534 663 
Albumin  
(32–47 g/l) 
31 30 23.8 
ALKP (<81 U/l)  436 65 115 
ALT (5–125 U/l)  65.5 277 50.4 
Blood smear  
Real-time PCR  positive (Ct value: 16) positive (Ct value: 26) positive (Ct value: 14) 
Serology (IFA)  negative (<1:50) 1:100 (2 weeks later 1:3200) negative (<1:50) 
Table 6  Three cases of canine granulocytic anaplasmosis in dogs presented to veterinarians in April (modified accord-
ing to Pantchev 2010a; methods according to Dyachenko et al. 2012); ALKP: Alkaline phosphatase, IFA (indirect 
immunofluorescence assay), ALT: alanine aminotransferase, CRP: C-reactive protein, Ct value (= cycle threshold: 
lower values represent higher amount of pathogen DNA).
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only 11.7 % were under oder equal the age of 1 year 
(Greig et al. 1996). In a Swedish study, 28.6% of 
the dogs were over the age of 9 and 0% under the 
age of 1 (Egenvall et al. 1997). The pattern is simi-
lar in humans, as patients are commonly in the 
50- to 60-year age range, with children only rarely 
affected (Diniz and Breitschwerdt 2012). A possible 
explanation might be that repeated reinfection is 
necessary (hence older dogs), or a fully developed 
immune system is required, because Anaplasma 
spp. impact on various immunological processes 
in order to survive (Egenwall et al. 1997; Carrade 
et al. 2009; Woldehiwet 2010). There appears to be 
a degree of seasonality, in parallel with the emer-
gence of ticks (approximately from April to Sep-
tember; Kohn et al. 2008; Carrade et al. 2009). The 
characteristic clinicopathological abnormalities 
and the options for specific diagnosis are illustrat-
ed in the form of a diagram in Table 6 on the basis 
of three case examples (one each from Germany, 
the Netherlands and Austria).
Among the clinicopathological abnormalities, 
thrombocytopenia is the most important altera-
tion in more than 80 % of cases (Greig et al. 1996; 
Kohn et al. 2008; Carrade et al. 2009; Diniz and 
Breitschwerdt 2012). In one study, over half of the 
dogs reacted positively in a platelet-bound antibody 
test (Kohn et al. 2008). Other important abnor-
malities are lymphopenia (approx. 50 %), anaemia 
(approx. 60 %; mild to moderate, non-regenerative 
and normochromic), occasionally hypoalbuminae-
mia (mild to moderate) and an increase in alka-
line phosphatase and possibly other liver enzymes 
such as alanine aminotransferase (Table 6). Pro-
teinuria has been also described. A relatively new 
but definitely additional promising test appears to 
be the measurement of C-reactive protein (CRP), 
which can increase by up to tenfold in the acute 
phase of the disease (Pantchev 2010a). CRP levels 
might also be useful in monitoring the success of 
treatment, as they are not influenced by the admin-
istration of glucocorticoids, for example (Kjelgaard-
Hansen et al. 2006). Because of the seronegativity 
of some clinical cases (see Table 6), a confirmed 
diagnosis of CAG, from a single diagnostic test, 
may not be sufficient. Following experimental 
infection (with various isolates; i.v. with autologous 
infected neutrophils, not with ticks), dogs tested 
positive by PCR (blood) from 2 days p.i., serocon-
version occurred after 10 – 14 days p.i. using IFA, 
and morulae were visible in blood smears between 
days 10 and 11 p.i. (Scorpio et al. 2011). This shows 
that the results of diagnostic tests will vary accord-
ing to the time point post-infection (Fig. 11) and 
that concurrent use of serology and PCR will there-
fore increase the likelihood of an accurate diagnosis 
(Table 7).
The options for specific diagnosis in veterinary 
practice are limited to the detection of intracyto-
plasmatic inclusions (morulae) in neutrophils (in 
stained blood smears) during the acute infection 
phase and to indirect serological procedures using 
the SNAP® 4Dx® rapid test (currently available as 
SNAP® 4Dx® Plus for the additional detection of 
antibodies to Ehrlichia ewingii). This assay detects 
antibodies (qualitatively; 17 – 30 days p.i.; Scorpio 
Table 7 Two ways to detect a pathogen (serology versus PCR): what are the differences?
Serology PCR
Detects the immunological antibody response of the 
infected host 
Detects nucleic acid of the infectious agent 
Antibodies persist over time – suitable for screening
The infectious agent (or its DNA) must be present in the  
sample – suitable in the acute phase of the disease 
The immune response takes time, so clinical symptoms 
may appear before a measurable antibody response 
A positive result indicates the presence of the agent, but 
a negative result does not necessarily rule out infection 
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et al. 2011) to a major surface protein (p44/MSP2) 
of A. phagocytophilum. Antibodies to Anaplasma 
platys are also detected, as was shown in a experi-
mental study (Gaunt et al. 2010). An advantage of 
this test is the option of simultaneously detecting 
antibodies to the C6 peptide of Bbsl, and for dogs 
with a history of travel in endemic regions, anti-
bodies to E. canis and heartworm antigen. Further 
diagnostic options in reference laboratories include 
IFA for serology and specific real-time PCR tests 
for molecular detection. IFA allows semi-quantita-
tive determination of antibody levels in blood (titre 
determination). This is useful in order to observe 
fluctuations (increase or decrease) in antibody 
response. Seroconversion occurs two to five days 
after the initial appearance of morulae in periph-
eral blood (see above; Scorpio et al. 2011). Titres 
then increase within 2 to 3 weeks (see also Table 6; 
Scorpio et al. 2011) and decrease between 4 to 
8 months after the detection of inclusions within a 
blood smear and treatment with doxycycline (Egen-
wall et al. 1997). An increase in titres in some dogs 
in the Swedish study after the next (tick) season 
can most probably be explained by asymptomatic 
re-infections. A disadvantage of the A. phagocy-
tophilum IFA compared with tests using specific 
peptides (e.g. SNAP® 4Dx®; Chandrashekar et al. 
2010) is possible cross-reactivity with E. canis anti-
bodies. The strength of the cross-reactivity of such 
sera when tested with A. phagocytophilum antigen 
increases with the duration of the E. canis infection 
and the E. canis antibody titre (Harrus et al. 2012). 
For example, in dogs infected experimentally with 
E. canis, no cross-reactivity with A. phagocytophi-
lum antigens was observed in the acute phase; how-
ever, cross-reactive antibodies were first detected 
on day 55 p.i. and were then found in all dogs by 
day 150 p.i. (Harrus and Waner 2011). The PCR for 
direct detection of pathogen DNA in blood is more 
sensitive than the microscopic scanning of stained 
blood smears, demonstrated with experimentally 
infected dogs. The dogs tested positive for Anaplas-
ma spp. DNA, 6 to 8 days before morulae could be 
detected in peripheral blood (Scorpio et al. 2011). 
The authors also showed that in the canine model 
the bacterial load (quantitative real-time PCR) cor-
related with platelet decline, observed until the end 
of the study period (60 days p.i.). However, there
Fig. 11 Results of diagnostic tests 
according to time p.i.; 
dog A: shortly after infection (the 
dog may already show symptoms): 
pathogen DNA is present in blood 
samples and can be detected by PCR; 
no immune response occurred so far, 
antibody detection is not possible; 
dog B: shows clinical signs: PCR result 
is positive although the number of 
pathogens in the blood is already 
decreasing; serology is also positive 
due to a suffi cient immune response, 
but the antibody level is still low 
(rising; color triangle represents over-
lap zone of both tests), 
dog C: weeks or months elapsed since 
infection; the dog may be asympto-
matic: PCR is negative as pathogens 
are no longer circulating in the blood; 
serology is positive with a potentially 
high IFA titre; schematic display 












Dog A Dog B Dog C
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 were some differences based on the A. phagocyto-
philum strain and cell type used for i.v. infection. 
PCR allows the differentiation of A. phagocyt-
ophilum and A. platys (the latter is important in 
dogs with a history of travel to endemic regions; 
Dyachenko et al. 2012), which again can cross-
react serologically (Gaunt et al. 2010). There have 
been recent reports of PCR-positive findings in skin 
biopsies from dogs with skin lesions of unknown 
origin and a histological picture of vasculitis (Ber-
zina et al. 2014). The involvement of A. phagocy-
tophilum in such cases and the interpretation 
of DNA detection in skin tissue require further 
clarification.
Canine babesiosis 
For the diagnosis of canine babesiosis the following 
points should be considered (according to Pantchev 
2012a): anamnesis including history of travel in 
endemic areas and tick infestation, blood transfu-
sion or other possible non-vector-borne transmission 
routes (see above), clinical findings and laboratory 
abnormalities, direct pathogen detection in blood 
smears stained using Giemsa, Wright or Diff-Quik 
or DNA detection by PCR, and indirect patho-
gen detection by serology (ELISA, IFA). Typical 
laboratory findings, which differ depending on the 
Babesia species (see Tables 2 and 3), are haemolytic 
anaemia (initially non-regenerative, normocytic 
and normochromic, later regenerative, macrocytic 
and hypochromic), secondary immunohaemolytic 
anaemia with positive Coombs test, spherocytes, 
leukocytosis with a left shift in many cases, and 
thrombocytopenia and neutropenia. Further clinic-
opathological abnormalities are haemoglobinuria, 
bilirubinuria, bilirubinaemia and proteinuria (due 
to intravascular haemolysis), an increase in aspar-
tate aminotransferase, alanine aminotransferase 
(hepatopathy) and azotaemia, and chronic hypoal-
buminaemia (hepatopathy and glomerulopathy) 
(Ayoob et al. 2010; Birkenheuer 2012). The speci-
fic diagnostic options in veterinary practice during 
the acute phase are limited to stained blood 
smears, which allow differentiation between large 
(Fig. 12A) and small Babesia species. Capillary 
blood or buffy coat preparations are more suit-
able in many cases, because infected erythrocytes 
sequestrate in capillaries and Babesia tend to 
invade reticulocytes rather than mature eryth-
rocytes (Irwin 2009; Ayoob et al. 2010; Ogo et al. 
2011). Differentiation of large versus small forms 
is usually possible, except in rare cases of atypical 
Fig. 12  A: large Babesia (arrows); in this case characterized as Babesia rossi by SSU rDNA amplification with  
subsequent sequencing according to Carret et al. (1999) in a stained blood smear from a dog imported from  
South Africa  
B: atypical, smaller, rounded form of Babesia canis (arrow) characterized by SSU rDNA amplification and sequencing 
(see above); scale bar = 20 μm
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B. canis stages which unexpectedly can take on a 
small, rounded form (Fig. 12B). In these cases, PCR 
is indicated to ensure reliable differentiation (see 
also Demeter et al. 2011). Small and large Babesia 
species should be clearly differentiated at diagno-
sis, because they require different treatment pro-
tocols (see below).
Further testing options in a reference laboratory 
include quantitative serology and PCR. Large 
Babesia (B. canis, B. vogeli and B. rossi) are known 
to cross-react with each other’s antigen using IFA, 
even though they produce stronger IFA reactions 
in homologous systems (e.g. B.  canis antigen 
with B. canis-infected dog; Uilenberg et al. 1989; 
Jongejan et al. 2011). Beyond that, Babesia can 
also cross-react at genus level (e.g. B. canis and 
B. gibsoni), irrespective of the test used (IFA or 
ELISA), if the test uses whole-cell antigen (Belton 
2003; Birkenheuer et al. 2003; Ogo et al. 2011; own 
observations). Within the above-mentioned whole-
cell B. canis ELISA, cross-reaction with B. vogeli 
has already been shown (Dyachenko et al. 2012). 
Furthermore, seven out of nine molecularly con-
firmed B. gibsoni canine samples from Hungary, 
Sri Lanka, Germany and Czech Republic (seven 
of them were fighting dogs; real-time PCR accord-
ing to Dyachenko et al. 2012) also showed clearly 
positive reactions within the same B. canis ELISA 
(own unpublished observations). Additionally, 
three canine samples from mixed-breed dogs from 
Argentina (provided by Diego Fernando Eiras, Uni-
versidad Nacional de La Plata) suspected of having 
R. vitalii infections (merozoite stages in erythro-
cytes and leukocytes; see Eiras et al. 2014) reacted 
clearly positively as well (so far unpublished data). 
R. vitalii represents a large piroplasm occurring in 
Brazil and Argentina, and is proposed as the causa-
tive agent of canine rangeliosis (known as “bloody 
ears” disease; Eiras et al. 2014; see also Table 2). In 
general, serology cannot distinguish between ani-
mals with an acute or chronic infection (Irwin 2009; 
Ogo et al. 2011). Specific antibodies were detected 
on day 14 p.i. in 5 out of 7 dogs experimentally 
infested with D. reticulatus and infected with 
B. canis, and all animals seroconverted on days 
21 and 28 p.i. (with titres from 1:160 to > 1:2560; 
Jongejan et al. 2011). Similar results were achieved 
after sporozoite-induced subcutaneously infection 
with a French B. canis isolate (seroconversion at 
13 to 20 days p.i.; Uilenberg et al. 1981). Following 
experimental parenteral infection with B. vogeli 
in dogs, seroconversion occurred seven days p.i., 
with increasing titres from 14 to 21 days p.i. and 
maximum titres of 1:1280 to 1:5120 on 48 – 55 days 
p.i.. The antibody titres then decreased slightly 
until day 160 (approximately 2 dilution levels) to 
1:640 – 1:1280 (Brandao et al. 2003). The serology 
results for the treated group in the latter study 
(treatment with imidocarb, 7 mg/kg on days 
15 and 27 p.i.) were significantly different, as 
titres were lower and decreased faster (from day 
34 p.i. onwards). Capillary parasitaemia accom-
panied by fever was observed from 2 days p.i. 
until 41 days p.i. (intermittently during this time; 
Brandao et al. 2003). The disappearance of Babesia 
from the blood approximately correlated with the 
maximum antibody titres. Interestingly, antibody 
titres >1:320 showed a protective effect. In the 
latter experimental study parasitaemia had been 
observed 2 days p.i., which is earlier compared to 
the typical case in natural (tick-borne) infections of 
6 to 20 days p.i. (Brandao et al. 2003). This time lag 
may be due to the fact that, in the study cited, the 
dogs were inoculated with erythrocytes containing 
merozoites, while in natural settings the sporozo-
ites are the initial stages introduced by the ticks. 
After sporozoite-induced infection (subcutane-
ously with a French B. canis isolate) the prepatent 
period (blood smear from ear veins) was 5 – 7 days, 
and it was slightly shorter than the incubation 
period for fever (6 – 8 days; Uilenberg et al. 1981). 
The advantages of serology are the diagnosis of 
cases with low-level or intermittent parasitaemia 
(Uilenberg et al. 1981; Brandao et al. 2003) and of 
chronic infections (Irwin 2009). The limitations are 
cross-reactions (especially between different Babe-
sia species, see above) and false-negative findings 
in young or immunosuppressed dogs, or early in 
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 the course of infection before seroconversion has 
occurred (Ayoob et al. 2010). This final limitation 
requires the testing of paired sera, with the second 
taken after an interval of 2 to 3 weeks. It should 
also be considered that dogs in B. canis-endemic 
regions may show high titres without showing clin-
ical signs (Ayoob et al. 2010). Specific treatment 
with imidocarb and diminazene early in the course 
of infection (approx. 1 week p.i. after direct detec-
tion of B. canis in blood) prevented seroconversion 
in one out of eight dogs, as shown with an experi-
mental model (Beugnet et al. 2014).
Another important aspect of Babesia diagnostics 
in dogs is the use of PCR tests. The detection limit 
of PCR protocols is given variously as 50 organ-
isms per ml in one protocol and 9 per µl in anoth-
er (reviewed by Irwin 2009). In one study, it was 
1,300 times lower (better) than the detection limit 
of light microscopy (Birkenheuer et al. 2003). A 
single microscopic blood smear test, compared with 
PCR as the established gold standard, had a rela-
tive sensitivity of 38 % and a relative specificity of 
over 99 %; there was moderate agreement between 
the results of the two methods (kappa = 0.54; Glo-
bokar Vrhovec 2013). In the patient cohort tested 
by Globokar Vrhovec (2013; dogs living in Ger-
many), microscopy detected Babesia significantly 
more frequently in animals that had stayed within 
Germany compared to animals with a history of 
travel or imported animals. These data agree with 
the serological data obtained for Germany (see 
above). It is possible that a larger proportion of 
the animals with a history of travel were tested 
preventively irrespective of symptoms, whereas 
the animals that had stayed within Germany were 
tested on the basis of clinical suspicion. Another 
major advantage of PCR is that, following a posi-
tive Babesia PCR result, differentiation of Babesia 
species can subsequently be performed by either 
species-specific real-time PCR (Dyachenko et al. 
2012), or SSU rDNA amplification with subsequent 
sequencing (Beck et al. 2009). This is important in 
order to select an appropriate treatment, as large 
and small Babesia require different therapeutic 
approaches. The treatment of choice is imidocarb 
for large forms and a combination of atovaquone 
and azithromycin for B. gibsoni (Pantchev 2012a; 
Birkenheuer 2012). PCR itself has limitations, 
especially when no organisms are present in the 
blood (as in chronically infected animals), or if the 
parasitaemia is intermittent (Brandao et al. 2003; 
Irwin 2009). In these cases it is helpful to repeat 
PCR tests, or combine PCR with serology. In the 
above-mentioned study, which evaluated data from 
three different diagnostic procedures for B. canis 
(dogs living in Germany, 2004 to 2006), antibodies 
were detected (by IFA) in 11.5 % (n = 2,653) of dogs, 
parasitic stages were found in Giemsa-stained 
blood smears in 2.1 % of samples (n = 9,966) and 
DNA was detected (by conventional PCR) in 3.3 % 
of submitted blood samples (n = 15,155; Globokar 
Vrhovec 2013).
Another currently available tool used for detection 
of B. canis protein fractions in canine serum is the 
mass spectrometry (MALDI-TOF; Adaszek et al. 
2014). Latter authors identified a protein fraction 
of 51 – 52 kDa in samples of infected but not in con-
trol dogs. Further studies are necessary to estimate 
the sensitivity and specificity of this new technique 
for routine diagnostics with canine blood samples 
in comparison to currently applied species-specific 
real-time PCRs.
Prophylaxis
Prophylaxis is based on a range of different actions 
aimed at preventing infection or the development 
of disease following infection. There are four basic 
cornerstones of prophylaxis for TBD: vector proph-
ylaxis with acaricides / repellents (directed against 
the ticks which carry the pathogens), chemopro-
phylaxis (generally targeted directly against the 
pathogen), vaccination (by pathogen-specific vac-
cination) and behavioural prophylaxis (reducing 
vector exposure by avoiding risk areas during the 





According to the product information for certain 
acaricide-based products, some ticks already pre-
sent at the time of treatment are not killed within 
the first 48 hours and remain attached and visible. 
It is advisable to remove such ticks mechanically 
before starting prophylaxis. In one study, rotating 
devices (in order of success: tick-pliers (tick remov-
er / extractor), lasso, tick twister) proved better than 
pulling devices (tweezers, tick card). However, in 
regard to the tick mouthparts, there was no dif-
ference between the two groups (Robisch 2010). 
With the above-mentioned in mind, it is important 
to begin prophylaxis before the first ectoparasite 
exposure, e.g. efficacy against ticks develops within 
two days after applying a collar (using the exam-
ple of imidacloprid/flumethrin in Seresto®). Ticks 
infesting dogs in Europe do not tend to harm their 
hosts directly, with the main risk being that patho-
gen transmission can occur and disease potentially 
results from the infection. The applied compounds 
show different effects on ticks (repellency, anti-
feeding effect, disruption of attachment, expellency, 
killing effect), so it is important to use suitable aca-
ricides to kill the ticks as quickly as possible before 
pathogens are released. It is even better to prevent 
ticks from attaching (tick repellency sensu stricto; 
Halos et al. 2012). As one study showed, compounds 
with a repellent effect can prevent TBD (Anaplas-
ma / Borrelia) more efficiently than active substanc-
es, which only show a killing effect (Blagburn et al. 
2005). It is therefore important for veterinarians to 
take note of the relevant product information. 
Various acaricidal dog collars effective against 
ticks are licensed for use in Germany and Austria. 
They contain flumethrin / imidacloprid (Seresto®; 
duration of efficacy / DOE 7 to 8 months) or del-
tamethrin (Scalibor®; DOE 5 to 6 months) as active 
ingredients. Furthermore, a range of spot-on prod-
ucts is also available. It should be noted that prod-
ucts containing permethrin are to be avoided in 
cats because of their toxic effect on feline patients 
(e.g. Boland and Angles 2010). Permethrin-based 
products for dogs include: permethrin / imidacloprid 
(Advantix®; DOE for I. ricinus / R. sanguineus 
4 weeks, for D. reticulatus 3 weeks), permethrin 
only (Exspot®; DOE I. ricinus / R. sanguineus up 
to 4 weeks), permethrin / indoxacarb (Activyl Tick 
Plus®; DOE up to 5 weeks for I. ricinus, up to 
3 weeks for R. sanguineus), permethrin / fipronil 
(Frontect®; DOE 4 weeks), or permethrin / dinote-
furan / pyriproxyfen (Vectra 3D®; DOE for I. rici-
nus / R. sanguineus for 1 month, D. reticulatus 
up to 3 weeks). Non-permethrin-based products 
include: fipronil (Frontline® / Frontline Combo®; 
DOE up to 4 weeks), fipronil / amitraz/(S)-metho-
prene (Certifect®; DOE 5 weeks), or pyriprol (Prac-
tic®; DOE 4 weeks). Collars should be adjusted to 
the right size, thus not too tight or too loose, with 
two finger-widths between the collar and the ani-
mal’s neck. Spot-on products should be applied cor-
rectly, thus the spot-on solution should be applied 
to the skin, and not the hair of the dog, and lick-
ing off by the animal itself or companion animals 
needs to be prevented. Oral products using the new 
active substance class of isoxazolines are currently 
also available as fluralaner (Bravecto®; DOE for 
I. ricinus, D. reticulatus, D. variabilis 12 weeks, for 
R. sanguineus 8 weeks), and afoxolaner (NexGard®; 
DOE for D. reticulatus, I. ricinus, R. sanguineus up 
to 1 month) in the form of chewable tablets for dogs. 
These are systemic acaricides, thus ticks have to 
attach to the host and start to feed in order to come 
into contact with the active ingredients. One cur-
rent study showed that afoxolaner was able to pre-
vent infection with B. canis in dogs experimentally 
infested with D. reticulatus ticks (Beugnet et al., 
2014).
Vaccination
In controlled approval studies in dogs, ectopara-
siticides are usually tested using 50 adult ticks 
(EMEA/CVMP/005/00 Rev. 2). Consequently, 
100 % protection cannot be guaranteed in every 
case, especially in conditions of high tick exposure 
(numbers exceeding 50 ticks, e.g. hunting dogs). 
Seropositivity against A. phagocytophilum can 
also be used as an indicator of inadequate tick 
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prophylaxis. Vaccination may therefore be consid-
ered in such individual cases, if available. How-
ever, it should not be regarded as a replacement 
for tick prophylaxis. 
Borrelia vaccination
Borrelia vaccination has been a topic of controversy 
in recent years (Littman et al., 2006; Straubinger 
and Pantchev 2010; Greene et al. 2012; Pantchev 
2013). One reason for this is that clinical borre-
liosis is rare in dogs. Koch’s postulates have only 
been fulfilled experimentally for a clinical picture 
of transient fever, anorexia and clinical arthritis 
with lameness as well as reluctance to move, which 
was detected in puppies but not in dogs > 6 months 
(e.g. Appel et al. 1993; Straubinger 2000; Straub-
inger et al. 2000; Summers et al. 2005; Susta et al. 
2012; Wagner et al. 2012). In contrast to humans, 
no erythema migrans has been observed in dogs 
(Appel et al. 1993), but synovial lesions were sig-
nificant in infected dogs in all canine experimental 
studies (Appel et al. 1993; Summers et al. 2005; 
Susta et al. 2012; Wagner et al. 2012). After natu-
ral infection, lameness has been described in <5 % 
of dogs (Levy and Magnarelli 1992; McKenna et al. 
1995; Hovius et al. 2000; Chou et al. 2006; Littman 
et al. 2006), less than 1 – 2 % show kidney disease 
(Dambach et al. 1997; Chou et al. 2006; Littman 
2013), and the very rare cases with cardiac (Chou 
et al. 2006; Agudelo et al. 2011; Janus et al. 2014) 
and neurological (McKenna et al. 1995) involve-
ment are assumed rather than documented. No 
association was found between exposure to either 
Borrelia species (or A. phagocytophilum) and neu-
rological signs or inflammatory CNS disease in 
retrospective and prospective studies (Jäderlund 
et al. 2007, 2009), which have been subsequently 
confirmed by experimental infection (Krimer et al. 
2011). The different clinical picture of what is seen 
in veterinary practice and after experimental infec-
tion in dogs is still not well understood. It has been 
suggested that clinical illness might result from 
the host’s own inflammatory response (Straubin-
ger et al. 1998; Summers et al. 2005; Greene et al. 
2012). Experimental infections are performed usu-
ally only with a single breed (beagle, e.g. Summers 
et al. 2005), but for LN, a breed predisposition has 
been proposed. It might indicate that other breed-
related factors are necessary for disease devel-
opment, as proposed by Appel et al. (1993) and 
Horney and Stojanovic (2013). Moreover, multiple 
exposures in nature (reinfections) or other Borrelia 
spp. strains (e.g. also B. miyamotoi; Schreiber et al. 
2014) with a different plasmid content and viru-
lence (Hanincova et al. 2013) are additional pre-
conditions. For example, the risk of infection with 
Borrelia spp. for a single dog has been calculated 
to be up to 23 % per year in rural areas of eastern 
Austria (Leschnik 2014). Experimentally, disease 
could be induced after repeated exposure (3 times 
with 2-week intervals; tick nymphs with 16 % Bbss 
infection rate), but single exposure to 100 nymphs 
(same infection rate) did not result in clinical signs 
(Appel et al. 1993). This was supported later on 
by another study, where two cycles of tick chal-
lenge increased the frequency of clinical arthri-
tis compared to a single challenge (Straubinger 
et al. 1998). Furthermore, co-infections transmit-
ted by the common tick vector I. ricinus, especially 
A. phagocytophilum (Summers et al. 2005; Beall 
et al. 2008), but also other little-studied organisms 
in regard to their pathogenicity in the dog such as 
Bartonella spp. (Diniz et al. 2009), Rickettsia spp., 
(small) Babesia spp. (Appel et al. 1993; Skotarc-
zak 2014) or Candidatus Neoehrlichia mikurensis 
(Diniz et al. 2011; Schreiber et al. 2014; see Table 1), 
might play a role. In particular, co-infections (by 
different strains or species) are probably one of the 
least experimentally investigated areas to date, as 
is the (immunological) influence of repeated infec-
tions over a longer period of time.
A further reason for controversy regarding vacci-
nation in Europe in recent years is the fact, that 
different vaccines have been commercially avail-
able. For example, one vaccine contains only Bbss 
(isolated in France from an infected I. ricinus; 
Wiedemann and Milward 1999) and another con-
tains two isolates (B. garinii and B. afzelii). One 
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point of controversy is that, although B. garinii 
and B. afzelii are indeed commonly found in ticks 
in various parts of Europe (e.g. Piesman and Gern 
2004), their clinical relevance to dogs has not been 
conclusively demonstrated (see above). A new prod-
uct available in Germany and Austria is Merilym 
3 (inactivated Bbsl vaccine), which contains all 
three genospecies (Bbss, B. garinii and B. afzelii). 
A debatable question is whether this trivalent vac-
cine has advantages over purely Bbss-based prod-
ucts. Naturally infected dogs showing clinical signs 
of borreliosis have been found to have co-infec-
tions with Bbss and other genospecies (especially 
B. garinii; Hovius et al. 2000). Although the effects 
of co-infections in the dog have not yet been studied 
in an experimental model, co-infection with Bbss 
and B. garinii in a murine model showed a more 
severe progression of symptoms than an infection 
with Bbss alone (Hovius et al. 2007). Because it 
is assumed that OspA antibodies (the basis of the 
vaccine) are not cross-protective among Borrelia 
species (Straubinger et al. 2002; Töpfer 2005), it 
would be worth considering whether the vaccina-
tion regime should include other species (B. gari-
nii / B. afzelii) in addition to the canine pathogen 
Bbss recognized to date. Based on its principle of 
action (mainly induction of antibodies to OspA; 
see above), vaccination prevents future infection, 
because anti-OspA antibodies ingested during 
feeding inactivate the Borrelia directly within the 
tick’s gut (Straubinger and Pantchev 2010). Before 
vaccinating dogs, therefore, it is important to test 
adult dogs with an unknown infectious status and 
dogs that are already potentially infected. One rea-
son is, that vaccination has no effect on an existing 
Borrelia infection. Another reason is that dogs with 
high ACAC following vaccination with a lyophi-
lized product show very high levels of circulating 
immune complexes (Greene et al. 2012). Hebert and 
Eschner (2010), for example, included dogs in their 
vaccination programe only if they showed ACAC 
below 30 U/ml, together with normal blood and 
urine values. On the other hand, dogs with ACAC 
over 30 U/ml were treated (doxycycline 10 mg/kg 
q.d. for 28 days) and followed up after 30 days (lab-
oratory tests and clinical examination). Dogs with 
no abnormal findings were admitted to the vacci-
nation programe, with the Lyme Quant C6 ELISA 
being repeated six months later (see above). Dogs 
with glomerulonephritis and suspected LN may 
require a longer period of doxycycline administra-
tion. In such cases (UPC above 0.5), specific recom-
mendations regarding treatment and monitoring 
can be found in Goldstein et al. (2013).
Babesia vaccination
The homologous (strain-dependent) protection pro-
vided by vaccination with Pirodog® (not licensed in 
Germany) is around 80 to 90 % in endemic regions 
of France but lower in other regions. This vaccine 
contains soluble parasite antigen (SPA) of B. canis, 
and a positive antibody titre (>1:160) should devel-
op in around 75 % of animals following vaccination 
(source: product information). Broader protection, 
including protection against heterologous strains 
of B. canis, has been offered by the vaccine Nobivac 
Piro® (contains SPA of B. canis and B. rossi and was 
licensed for some years in the EU). This broader 
heterologous vaccine protection was achieved by 
the addition of B. rossi antigen (Schetters et al. 
1995; Schetters 2005; Irwin 2009; Ayoob et al. 
2010). However, this vaccine is not currently avail-
able on the European market.
Babesia chemoprophylaxis
The compound imidocarb, which has been used for 
chemoprophylaxis of infection with large Babesia, 
may induce potentially serious adverse effects, 
mainly due to cholinesterase inhibition, includ-
ing also anaphylactoid reactions and renal or liver 
impairment (Ayoob et al. 2010; Dyachenko et al. 
2012). Moreover, its prophylactic effect is of vari-
able duration (reported to range from 2 to 6 weeks 
at a dose of 3 – 6 mg/kg BW; Deplazes et al. 2006) or 
even not present in sporozoite-induced experimen-
tal infections with a French B. canis isolate (6 mg/
kg BW 2 to 5 weeks before infection; Uilenberg et al. 
1981). In combination, it is either not recommended 
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for use as chemoprophylaxis (Ayoob et al. 2010) or 
only for dogs under one year of age (with the recom-
mendation that older animals should be treated if 
symptomatic; Tenter and Deplazes 2006). Finally, 
imidocarb does indeed eliminate B. canis, but it also 
prevents the development of immunity, leaving dogs 
susceptible to reinfection (Brandao et al. 2003).
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